Chronic anti-ataxic actions of the novel thyrotropin-releasing hormone (TRH) analog, TA-0910, during and after repeated administration in rolling mouse Nagoya: Behavioral and pharmacokinetic studies

Biological and Pharmaceutical Bulletin

Volumn 20, Issue 1, 1997, Pages 36-39

  Kinoshita, Kiyoshi ^a   Fukushima, Takeshi ^a   Kodama, Yasuhiko ^a   Sugihara, Juko ^a   Yamamura, Michio ^a   Matsuoka, Yuzo ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

chronic anti ataxic effect; drug concentration; Rolling mouse Nagoya (RMN); TA 0910 (TRH analog)

Indexed keywords

GLUCOSE; PROTIRELIN DERIVATIVE; TALTIRELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BRAIN; BRAIN STEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; GLUCOSE UTILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; MOUSE; NERVE CELL NETWORK; NONHUMAN; TISSUE HOMOGENATE;

EID: 0031030377     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.20.36     Document Type: Article

References (24)

1. Sharp T., Benett G. W., Marsden C. A., Tulloch I. F., Regul. Pept., 9, 305-315 (1984a).
2. Sharp T., Tulloch I. F., Benetto G. W., Marsden C. A., Metcalf G., Dettmar P. W., Neuropharmacol., 23, 339-348 (1984b).
3. Yamamoto M., Shimizu M., Eur. J. Pharmacol., 166, 545-547 (1989).
4. Hashimoto T., Fukuda N., Jpn. J. Pharmacol., 53, 479-486 (1990).
5. Griffiths E. C., Clin. Sci., 73, 449-457 (1987).
6. Pitts L. H., Ross A., Chase G. A., Faden A. I., J. Neurotrauma, 12, 235-243 (1995).
7. Sobue I., Matsuoka Y., Katoh K., Sakuma A., "TRH and Spinocerebellar Degeneration," ed. by Sobue I., Elsevier, Amsterdam, 1986, pp. 173-188.
8. Bassiri R. M., Utiger R. D., J. Clin. Invest., 52, 1616-1619 (1973).
9. Metcalf G., Brain Res. Rev., 4, 389-408 (1982).
10. Yamamura M., Kinoshita K., Nakagawa H., Tanaka T., Maeda K., Ishida R., Jpn. J. Pharmacol., 53, 451-461 (1990).
11. Yamamura M., Kinoshita K., Nakagawa H., Ishida R., Jpn. J. Pharmacol., 55, 57-68 (1991a).
12. Yamamura M., Kinoshita K., Nakagawa H., Ishida R., Jpn. J. Pharmacol., 55, 69-80 (1991b).
13. Moriyasu M., Nasu M., Honda H., Sakamoto T., Yamamura M., Matsuoka Y., Folia Pharmacol. Jpn., 107, 285-297 (1996).
14. Kinoshita K., Fujitsuka T., Yamamura M., Matsuoka Y., Eur. J. Pharmacol., 274, 65-72 (1995a).
15. Chishima S., J. Pharmaceut. Biomed. Analy., 12, 795-804 (1994).
16. Kinoshita K., Watanabe Y., Asai H., Yamamura M., Matsuoka Y., Br. J. Pharmacol., 116, 3274-3278 (1995b).
17. Nishimura Y., Adv. Neurol. Sci., 19, 670-672 (1975).
18. Muramoto O., Kanazawa I., Ando K., Brain Res., 215, 295-304 (1981).
19. Muramoto O., Ando K., Kanazawa I., Brain Res., 237, 387-395 (1982).
20. Faden A. I., Hill G., Kubek M. J., Neuropeptides, 7, 11-18 (1986).
21. Salzman S. K., Knight P. B., Hirofuji E., Llados-Eckman C., Beckman A. L., Winokur A., Peptides, 8, 247-250 (1987).
22. Banda R. W., Means E. D., Fitzgerald M., Neurology, (Suppl.) 37, 285 (1987).
23. Iwasaki Y., Kinoshita M., Ikeda K., Takamiya K., Shiojima T., Neurosci. Lett., 101, 316-320 (1989).
24. Iwasaki Y., Ikeda K., Shiojima T., Kinoshita H., J. Neurol. Sci., 112, 147-151 (1992).